Qiaoliang Zhu
Overview
Explore the profile of Qiaoliang Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu W, Han L, He L, Peng W, Li Y, Tian W, et al.
Respir Res
. 2025 Feb;
26(1):71.
PMID: 40022153
Background: Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition, with its severity inversely related to the levels of Club cell 10 kDa secretory protein (CC10). The gene Lsm2,...
2.
Yang J, Wu Y, Zhu Q, Qu X, Ou H, Liu H, et al.
Bioorg Chem
. 2024 Jul;
150:107590.
PMID: 38955003
The c-ros oncogene 1 (ROS1), an oncogenic driver, is known to induce non-small cell lung cancer (NSCLC) when overactivated, particularly through the formation of fusion proteins. Traditional targeted therapies focus...
3.
Han L, Zhu W, Qi H, He L, Wang Q, Shen J, et al.
Int Immunopharmacol
. 2024 Feb;
129:111585.
PMID: 38325045
Cuproptosis, a novel mode of cell death, is strongly associated with a variety of diseases. However, the contribution of cuproptosis to the onset or progression of chronic obstructive pulmonary disease...
4.
Zhang H, Wen H, Zhu Q, Zhang Y, Xu F, Ma T, et al.
EBioMedicine
. 2024 Jan;
100:104971.
PMID: 38244291
Background: Neoadjuvant chemoimmunotherapy has offered novel therapeutic options for patients with locally advanced oesophageal squamous cell carcinoma (ESCC). Depicting the landscape of genomic and immune profiles is critical in predicting...
5.
Zhu W, Han L, Wu Y, Tong L, He L, Wang Q, et al.
Respir Res
. 2023 Nov;
24(1):297.
PMID: 38007424
Background: Chronic obstructive pulmonary disease (COPD), a chronic inflammatory lung disease, is a leading cause of morbidity and mortality worldwide. Prolonged cigarette smoking (CS) that causes irreversible airway remodeling and...
6.
Peng W, Qi H, Zhu W, Tong L, Rouzi A, Wu Y, et al.
Pulm Circ
. 2023 Oct;
13(4):e12295.
PMID: 37808899
LHQK is a patented Traditional Chinese Medicine (TCM) which is clinically used for acute tracheobronchitis, cough, and other respiratory diseases. Recent studies have proved that LHQK exhibits excellent clinical efficacy...
7.
Zhao G, Zhang H, Xu F, Lu C, Zhu Q, Grossi F, et al.
Transl Lung Cancer Res
. 2023 Feb;
12(1):141-149.
PMID: 36762056
Background: Pembrolizumab has been shown to be effective and safe in improving the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, the effectiveness and safty of pembrolizumab in...
8.
Yang J, Zhu Q, Wu Y, Qu X, Liu H, Jiang B, et al.
Front Oncol
. 2022 Dec;
12:992171.
PMID: 36465350
Protein-protein interactions (PPIs) play vital roles in normal cellular processes. Dysregulated PPIs are involved in the process of various diseases, including cancer. Thus, these PPIs may serve as potential therapeutic...
9.
Wang S, Shou H, Wen H, Wang X, Wang H, Lu C, et al.
BMC Pulm Med
. 2022 May;
22(1):209.
PMID: 35619108
Background: Tumor spread through air spaces (STAS) has been shown to adversely affect the prognosis of lung cancer. The correlation between clinicopathological and genetic features and STAS remains unclear. Method:...
10.
Zhang H, Liu Z, Wen H, Guo Y, Xu F, Zhu Q, et al.
Cancer Immunol Immunother
. 2022 Mar;
71(10):2511-2522.
PMID: 35278107
Background: Immune checkpoint blockade (ICB) has been improving patient outcomes of non-small cell lung cancer (NSCLC), but its effectiveness is highly subjective to individual tumor microenvironment. As dominant immune cells...